4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Receives $47.14 Consensus Target Price from Brokerages

Shares of 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) have been given an average rating of “Moderate Buy” by the nine research firms that are presently covering the stock, Marketbeat.com reports. One equities research analyst has rated the stock with a hold recommendation and eight have issued a buy recommendation on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $47.00.

Several equities analysts have commented on the stock. BMO Capital Markets dropped their target price on shares of 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, July 18th. Chardan Capital reiterated a “buy” rating and set a $39.00 price target on shares of 4D Molecular Therapeutics in a report on Thursday. HC Wainwright restated a “buy” rating and issued a $36.00 price objective on shares of 4D Molecular Therapeutics in a research note on Thursday. Royal Bank of Canada cut their price target on shares of 4D Molecular Therapeutics from $40.00 to $39.00 and set an “outperform” rating on the stock in a report on Thursday. Finally, Cantor Fitzgerald downgraded shares of 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a report on Monday, September 23rd.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock opened at $8.02 on Tuesday. 4D Molecular Therapeutics has a one year low of $7.32 and a one year high of $36.25. The company has a market cap of $416.80 million, a P/E ratio of -3.49 and a beta of 2.82. The firm has a 50-day moving average of $10.58 and a 200-day moving average of $17.31.

Hedge Funds Weigh In On 4D Molecular Therapeutics

Several large investors have recently modified their holdings of the business. Allspring Global Investments Holdings LLC boosted its holdings in 4D Molecular Therapeutics by 702.1% in the 1st quarter. Allspring Global Investments Holdings LLC now owns 3,457 shares of the company’s stock worth $110,000 after buying an additional 3,026 shares during the period. nVerses Capital LLC bought a new position in shares of 4D Molecular Therapeutics in the third quarter worth $40,000. Values First Advisors Inc. purchased a new position in shares of 4D Molecular Therapeutics in the third quarter valued at $57,000. Quest Partners LLC raised its stake in shares of 4D Molecular Therapeutics by 17,409.1% during the 2nd quarter. Quest Partners LLC now owns 5,778 shares of the company’s stock valued at $121,000 after purchasing an additional 5,745 shares during the period. Finally, Entropy Technologies LP purchased a new stake in 4D Molecular Therapeutics during the 1st quarter worth about $239,000. Hedge funds and other institutional investors own 99.27% of the company’s stock.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.